No Data
No Data
Are Robust Financials Driving The Recent Rally In Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock?
Baiyunshan (00874.HK) shares were reduced by 0.186 million shares by Norges Bank.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on September 30, 2024, baiyunshan ph (00874.HK) was reduced by Norges Bank on the exchange at an average price of HK$20.6237 per share, reducing 0.186 million shares, involving approximately HK$3.836 million. After the reduction, Norges Bank's latest number of shares held is 35.095 million shares, and the shareholding percentage has decreased from 16.04% to 15.96%.
BAIYUNSHAN PH: (1) POLL RESULTS OF THE SECOND EXTRAORDINARY GENERAL MEETING IN 2024 HELD ON 27 SEPTEMBER 2024; AND (2) PAYMENT OF INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2024
BAIYUNSHAN PH: Interim Report 2024
Baiyunshan (600332.SH): Pharmaceutical products of its subsidiary have passed the consistency evaluation of generic drugs.
GeLongHui September 18th, baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Pharmaceutical Factory (referred to as “Baiyunshan Pharmaceutical Factory”), has received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration. The Azithromycin Capsules have passed the generic drug quality and efficacy consistency evaluation. Azithromycin belongs to the macrolide antibiotics category, with characteristics such as a broad spectrum of antibacterial activity, fast oral absorption, and a long half-life. It is mainly used to treat: (1) Acute pharyngitis and acute tonsillitis caused by Staphylococcus aureus; (2) Sinusitis caused by susceptible bacteria,
HK stock news | Baiyunshan (00874) fell more than 3%, second quarter performance under pressure, and Morgan Stanley lowered the company's profit expectations and target price.
Baiyunshan (00874) fell more than 3%, as of the time of writing, it fell 3.02%, to HK$16.7, with a turnover of HK$2.9731 million.
No Data
No Data